# Novel Biomarker Could Predict Resistance to Immunotherapy, Study Finds

Scientists at Northwestern Medicine have discovered a biological marker that predicts which cancer patients are more resistant to immunotherapy. Dubbed USP22, the marker also points to a potential treatment target for non-responders. Findings published in The Journal of Clinical Investigation have the potential to transform care for patients whose current options remain limited.

 Given the pace at which enterprises like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are making progress in their research and…

 Read More>>

 About TinyGems

 TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.TinyGems.com

 Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

 TinyGemsAustin, Texaswww.TinyGems.com512.354.7000 OfficeEditor@TinyGems.com

 TinyGems is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/tg/novel-biomarker-could-predict-resistance-to-immunotherapy-study-finds/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/new-biomarker-usp22-predicts-cancer-immunotherapy-resistance/e2b4f0724629d22f590c75c237c9003c) 


Pickup - [https://advos.io/en](https://advos.io/en/northwestern-medicine-researchers-identify-biomarker-predicting/202525621)

Pickup - [https://burstable.news](https://burstable.news/news/202512/345859-usp22-biomarker-discovery-may-predict-immunotherapy-resistance-in-cancer-patients)

Pickup - [https://platzennachrichten.de/nachrichten](https://platzennachrichten.de/nachrichten/202512/335400-usp22-biomarker-entdeckung-konnte-immuntherapie-resistenz-bei-krebspatienten-vorhersagen)

Pickup - [https://estallarnoticias.com/noticias](https://estallarnoticias.com/noticias/202512/335380-descubrimiento-del-biomarcador-usp22-podria-predecir-resistencia-a-la-inmunoterapia-en-pacientes-con-cancer)

Pickup - [https://actueclair.com/actualites](https://actueclair.com/actualites/202512/335968-la-decouverte-du-biomarqueur-usp22-pourrait-predire-la-resistance-a-limmunotherapie-chez-les-patients-atteints-de-cancer)

Pickup - [https://oestouro.com/noticias](https://oestouro.com/noticias/202512/335312-descoberta-do-biomarcador-usp22-pode-prever-resistencia-a-imunoterapia-em-pacientes-com-cancer)

Pickup - [https://fishervista.com/en](https://fishervista.com/en/northwestern-medicine-researchers-identify-biomarker-predicting/202525621)

Pickup - [https://www.newsworthy.ai/curated](https://www.newsworthy.ai/curated/novel-biomarker-usp22-identified-as-predictor-of-immunotherapy-r/202525621)
 

 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/2512/17/kissk4aJ.webp)